Pommier F, Sioufi A, Godbillon J
Novartis Pharma, Bioanalytics and Pharmacokinetics, Rueil Malmasion, France.
J Chromatogr B Biomed Sci Appl. 1997 Dec 5;703(1-2):147-58. doi: 10.1016/s0378-4347(97)00400-3.
An analytical method for the simultaneous determination of imipramine (IMI) and its N-desmethyl metabolite, desipramine (DIMI) in human plasma by capillary gas chromatography-mass selective detection (GC-MS), with D4-imipramine (D4-IMI) and D4-desipramine (D4-DIMI) as internal standards, was developed and validated. After addition of the internal standards, the compounds were extracted from plasma at basic pH into n-heptane-isoamyl alcohol (99:1, v/v), back-extracted into acidic aqueous solution and re-extracted at basic pH into toluene. Desipramine and D4-desipramine were converted into their pentafluoropropionyl derivatives. The compounds were determined by gas chromatography using a mass selective detector at m/z 234 for IMI, m/z 238 for D4-IMI, m/z 412 for DIMI and m/z 416 for D4-DIMI. The method was applied to clinical samples.
建立并验证了一种采用毛细管气相色谱 - 质量选择性检测(GC - MS)同时测定人血浆中丙咪嗪(IMI)及其N - 去甲基代谢物地昔帕明(DIMI)的分析方法,以D4 - 丙咪嗪(D4 - IMI)和D4 - 地昔帕明(D4 - DIMI)作为内标。加入内标后,将化合物在碱性pH条件下从血浆中萃取到正庚烷 - 异戊醇(99:1,v/v)中,再反萃取到酸性水溶液中,然后在碱性pH条件下重新萃取到甲苯中。地昔帕明和D4 - 地昔帕明被转化为它们的五氟丙酰基衍生物。使用质量选择性检测器通过气相色谱法测定化合物,IMI在m/z 234处检测,D4 - IMI在m/z 238处检测,DIMI在m/z 412处检测,D4 - DIMI在m/z 416处检测。该方法应用于临床样本。